What is Exenatide?
Category: Prescription Drugs
Most popular types: Bydureon Byetta
Exenatide is an add-on therapy for patients with Type 2 diabetes that are not adequately controlled with oral hypoglycemic medications. It is a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist. It is available as Byetta (injected twice-daily) and Bydureon (once-weekly).
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Diabetes type 2 | 1302 | 43 | |
| Weight loss | 10 | 7 | |
| Elevated blood sugar (hyperglycemia) | 7 | 5 | |
| General health | 2 | 1 | |
| Birth control | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 9 | |
| Moderate | 6 | |
| Mild | 12 | |
| None | 22 |
Commonly reported side effects and conditions associated with Exenatide
| Side effect | Patients | Percentage |
|---|---|---|
| Nausea | 6 | |
| Headaches | 3 | |
| Dizziness | 2 | |
| Injection site bumps | 2 | |
| Low blood sugar (hypoglycemia) | 2 | |
| Bruising | 1 |
Why patients stopped taking Exenatide
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Doctor's advice | 15 | |
| Side effects too severe | 11 | |
| Other | 10 | |
| Did not seem to work | 8 | |
| Course of treatment ended | 2 | |
| Personal research | 2 | |
| Change in health plan coverage | 1 |
Duration
Stopped taking Exenatide
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 11 | |
| 1 - 6 months | 7 | |
| 6 months - 1 year | 7 | |
| 1 - 2 years | 4 | |
| 2 - 5 years | 9 | |
| 5 - 10 years | 1 | |
| 10 years or more | 1 |
What people switch to and from
Patients started taking Exenatide after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Metformin (Metformin ER) | 5 | |
| Liraglutide (Victoza) | 4 | |
| Glimepiride (Amaryl) | 3 | |
| Glipizide (Glipizide ER) | 1 | |
| Glyburide-Metformin (Glucovance) | 1 |
Patients stopped taking Exenatide and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Dulaglutide (Trulicity) | 4 | |
| Liraglutide (Victoza) | 4 | |
| Insulin Lispro (Humalog) | 3 | |
| Metformin (Metformin ER) | 3 | |
| Dapagliflozin (Farxiga) | 2 |
Last updated: